FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine
standalone flu vaccine called tNIV. Robert Walker, Novavax’s chief medical officer, said that the FDA “satisfactorily addressed all clinical hold issues.” Walker confirmed that trial activities will resume as soon as possible. Novavax’s upcoming ...
The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for ...
A trial participant who’d received the shot in Jan. 2023 later developed motor neuropathy, or muscle weakness, leading the ...
A fresh wave of disinformation about vaccines is flaring amid the 2024 campaign. The FDA's top vaccine official believes ...
Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter ...
On September 20, 2024, the U.S. Food and Drug Administration (FDA) approved the first influenza (flu) vaccine for at‑home use. The vaccine, ...
today announced that the U.S. Food and Drug Administration (FDA) has issued a “Study Can Proceed” notification for the Company’s Investigational New Drug (IND) application, ARCT-2304, a ...
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback